News

Phase 2 trial of TX45 for PH-HFpEF beginning to enroll patients

A Phase 2 clinical trial of TX45, Tectonic Therapeutic’s investigational therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has begun enrolling eligible patients. The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages…

Prostacyclins show promise as CTEPH treatment: Meta-analysis

Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…

Rehabilitation exercises help PAH transplant candidates: Study

Adults with severe pulmonary arterial hypertension (PAH) awaiting lung transplants can safely participate in pulmonary rehabilitation and maintain or improve exercise capacity, a study found. Pulmonary rehabilitation led to modest improvements in measures of aerobic training and in muscle training volumes with no major adverse events. However, participation in…

Long-term oxygen therapy improves exercise capacity in PH

Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42…

New INOmax inhaled nitric oxide device now available to US NICUs

A new device to deliver inhaled nitric oxide gas to newborns with pulmonary hypertension (PH), is now available for use in hospital neonatal intensive care units (NICUs) across the U.S. The rollout follows recent approval from the U.S. Food and Drug Administration of the next-generation device, the INOmax…

Tiny vesicles may reduce vascular remodeling in PH: Rat study

Exosomes, a type of small vesicle released by mesenchymal stem cells (MSCs), helped reduce vascular remodeling and ease pulmonary hypertension (PH) symptoms in a rat model of the disease, a study found. Exosome effects were tied to a modulation of the NF-kB/BMP pathway involved in vascular remodeling, a set…